Probiotics in the management of inflammatory bowel disease

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Penner, Robert M ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIFIDOBACTERIUM ANIMALIS EXTRACT; BIFIDOBACTERIUM BREVE EXTRACT; BIFIDOBACTERIUM LONGUM EXTRACT; BIFIDOBACTERIUM LONGUM INFANTIS EXTRACT; ESCHERICHIA COLI EXTRACT; LACTOBACILLUS ACIDOPHILUS EXTRACT; LACTOBACILLUS BULGARICUS EXTRACT; LACTOBACILLUS CASEI EXTRACT; LACTOBACILLUS DELBRUECKII EXTRACT; LACTOBACILLUS PLANTARUM EXTRACT; LACTOBACILLUS RHAMNOSUS EXTRACT; MESALAZINE; MUTAFLOR; NATURAL PRODUCT; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; SACCHAROMYCES BOULARDII EXTRACT; STREPTOCOCCUS SALIVARIUS EXTRACT; STREPTOCOCCUS THERMOPHILUS EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BIFIDOBACTERIUM; CLINICAL TRIAL; CROHN DISEASE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SUBSTITUTION; ENTERITIS; EVIDENCE BASED MEDICINE; HOST PATHOGEN INTERACTION; HUMAN; ILEITIS; INTESTINE ENDOSCOPY; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS BULGARICUS; MAINTENANCE THERAPY; POSTOPERATIVE PERIOD; PROPHYLAXIS; REMISSION; TREATMENT DURATION; ULCERATIVE COLITIS; DIET THERAPY; REVIEW;

HUMANS; INFLAMMATORY BOWEL DISEASES; POUCHITIS; PROBIOTICS;

EID: 34547648529     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658-664.
2. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119:305-309. Abstract
3. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114. Abstract
4. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-515. Abstract
5. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol. 2003;38:409-414. Abstract
6. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209. Abstract
7. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47:876-884. Abstract
8. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5.
9. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactabacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-457. Abstract
10. McCarthy J, O'Mahony L, Dunne C, et al. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's disease. Gut. 2001;49, Suppl 111:2447.
11. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997;25:653-658.
12. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464. Abstract
13. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405-409. Abstract
14. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology. 2000;118:A781.
15. Rembacken BJ, Snelling AM, Hawkey-PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639. Abstract
16. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-1141. Abstract
17. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-249. Abstract
18. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697-698. Abstract
19. Fedorak RN, Gionchetti P, Campieri M, et al. VSL3 Probiotic Mixture Induces Remission in Patients with Active Ulcerative Colitis. Gastroenterology. 2003;124:A377.
20. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-858. Abstract
21. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623. Abstract
22. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63. Abstract
23. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108. Abstract